Vanguard Capital Management’s Denali Therapeutics DNLI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$140M Buy
6,751,225
+475,496
+8% +$11.1M ﹤0.01% 1323
2026
Q2
$161M Buy
6,275,729
+127,772
+2% +$2.63M ﹤0.01% 1273
2026
Q1
$118M Buy
+6,147,957
New +$122M ﹤0.01% 1379

Other funds holding DNLI

Vanguard Capital Management's DNLI Position: Q3 2026 in Review

Vanguard Capital Management increased its Denali Therapeutics (DNLI) stake by 7.6% in Q3 2026, buying an estimated $11.1M and bringing the position to 6,751,225 shares worth $140M. The position accounts for ﹤0.01% of the portfolio, ranked #1323.

Vanguard Capital Management first reported a position in DNLI in Q1 2026 and has held it in 3 quarters since. The position peaked at $161M in Q2 2026. 287 funds tracked by Wall St. Rank hold DNLI as of Q3 2026.

  • Vanguard Capital Management held 6,751,225 shares of Denali Therapeutics worth $140M as of Q3 2026.
  • Vanguard Capital Management bought 475,496 Denali Therapeutics shares in Q3 2026, an estimated $11.1M.
  • Denali Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #1323 holding.
  • Vanguard Capital Management first reported a position in Denali Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Denali Therapeutics position peaked at $161M in Q2 2026.
  • 287 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.